Bone Metabolism Archives - Endocrinology Advisor

Bone Metabolism

FDA Approves First-in-Class Sclerostin-Inhibitor for Postmenopausal Women at High Risk for Fracture

The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapies.

Next post in Bone Metabolism